KOSDAQ: 195940

China’s Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South Korea’s HK inno.N Corporation (KOSDAQ: 195940) for the development and commercialization of ecnoglutide injection (XW003), a novel glucagon-like peptide-1 (GLP-1) analog, for the treatment of type 2 diabetes, obesity, and metabolic associated severe hyperglycemia (MASH)…